Alteration of drug biotransformation and elimination during infection and inflammation.
about
Toxicity of amphetamines: an updatePharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected PatientsRegulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}A model for the induction of autism in the ecosystem of the human body: the anatomy of a modern pandemic?Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfateSalmonella induces prominent gene expression in the rat colonDietary soyasaponin supplementation to pea protein concentrate reveals nutrigenomic interactions underlying enteropathy in Atlantic salmon (Salmo salar).HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.Interactions of herbs with cytochrome P450.The 2001 Veylien Henderson Award of the Society of Toxicology of Canada. Positive and negative transcriptional regulation of cytochromes P450 by polycyclic aromatic hydrocarbons.Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.Is autism a member of a family of diseases resulting from genetic/cultural mismatches? Implications for treatment and prevention.Organotypic liver culture models: meeting current challenges in toxicity testing.Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.Regulation of drug metabolism and disposition during inflammation and infection.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipientsDrug metabolism by tumours: its nature, relevance and therapeutic implications.Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models.Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop.Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury.Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines.Treprostinil Improves Hepatic Cytochrome P450 Activity during Rat Liver Transplantation.Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.Nuclear receptors in the cross-talk of drug metabolism and inflammation.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients.Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.Hyperlipidemia exacerbates cerebral injury through oxidative stress, inflammation and neuronal apoptosis in MCAO/reperfusion rats.The acute phase response induced by Escherichia coli lipopolysaccharide modifies the pharmacokinetics and metabolism of florfenicol in rabbits.Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.Pharmacokinetics of florfenicol after intravenous administration in Escherichia coli lipopolysaccharide-induced endotoxaemic sheep.Noscapine may increase the effect of warfarin.Chenodeoxycholic acid increases the induction of CYP1A1 in HepG2 and H4IIE cells.Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease.Regulation of drug transporter mRNA expression by interferon-γ in primary human hepatocytes.Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.
P2860
Q22252794-9DD0CF46-8A9E-4F75-BFF7-E223BD679505Q28551880-46C2DBE1-ED25-4201-93ED-EE64B9AA669CQ28578667-3CE81E6F-65AD-4977-A571-FB266DCB68E2Q30371235-CF4DEB82-30A2-40EF-93AE-465A2CE24755Q33284842-B33D92D0-2CFD-4259-A378-BD4B2901E544Q33298670-9AD39B37-8DD6-404C-8470-7939B392995EQ34322504-9A360F6C-66C3-4ADF-9FC6-78A75C917C5BQ35033499-EC28B98B-DC79-434D-8487-005E2D75F5D1Q35085032-3FC62460-02E7-4DA8-9F49-191010A3EA56Q35094599-B918B4D6-08FA-493D-B950-B84D3469E64EQ35820291-68F4C515-D965-4B22-AFA9-B33C2750827BQ35827510-7CFCC2B1-0C30-4DF4-8978-5F3EA52C5B43Q36168925-FD5C19B4-52F5-4C84-9FF4-004978429CB2Q36178225-E832A4B4-8DCA-42A5-95AF-409030F9CF72Q36178387-BFB6A5D6-CE01-4FD1-946A-962A7F66FA66Q36544874-47F0DD6A-5AE2-4207-8E6C-4D827D9A8B20Q36887922-E734FFF3-2C27-438E-88BF-9DF93EC5869BQ36969224-A3248742-EEB4-4127-8C69-9AE33232C520Q37008879-D0152B06-3208-4988-8C92-917D3C9DAB00Q37187997-7E587143-48D3-4B60-A3C8-BB9FEBD4DB5EQ37284901-07E9B04D-C655-4C2C-91A4-4254E8278CA8Q37311022-2A881F39-C1E6-44CA-9BA1-0C1B0834A8BBQ37397205-B984751E-5892-46F5-BAF5-97AC2B9AAD1BQ37604385-C5CD214F-A001-4C99-B25E-7F4242C6A8E1Q37613871-588B371F-102A-4C0F-A12D-C0C09C5567BDQ37964754-E4DA5E4E-2BCC-49D4-8842-E8263457DC62Q38074993-A2F9F6A9-1844-4231-AA9C-14FE1CD171B6Q38634986-7DADBC81-77E2-47D9-A028-2D6411289CA2Q38888350-E763A17A-6DE4-4BEE-A7EA-EC64A386913EQ39296300-6FFA5AEB-03DD-40D1-99FD-83DD25272B19Q40051462-402C317B-3F1B-4CFA-893D-6AB678EA7BD4Q40665060-0D09A1B5-6CDC-4D42-AE85-BECD8C018211Q40903197-F86410B7-345F-430C-85A2-5AD59F8F13F3Q41191596-000B3DC8-A012-4A88-B352-81ED09BB99EBQ41735896-B06716F1-B375-40C5-9948-3C2FB9C3E6BDQ43110258-32B55369-0066-4C7B-83C0-CDBD5042AC52Q43147406-BE146D6F-B52E-4D78-A441-7ADD976CCDFCQ43867191-145F2817-998A-444F-99A7-11703ADC88BAQ44363021-C379444D-E68C-4913-B182-F4DDD1A54F06Q45958144-5342CBD3-D3ED-4309-91F1-3AD0229E2221
P2860
Alteration of drug biotransformation and elimination during infection and inflammation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Alteration of drug biotransformation and elimination during infection and inflammation.
@ast
Alteration of drug biotransformation and elimination during infection and inflammation.
@en
Alteration of drug biotransformation and elimination during infection and inflammation.
@nl
type
label
Alteration of drug biotransformation and elimination during infection and inflammation.
@ast
Alteration of drug biotransformation and elimination during infection and inflammation.
@en
Alteration of drug biotransformation and elimination during infection and inflammation.
@nl
prefLabel
Alteration of drug biotransformation and elimination during infection and inflammation.
@ast
Alteration of drug biotransformation and elimination during infection and inflammation.
@en
Alteration of drug biotransformation and elimination during infection and inflammation.
@nl
P1476
Alteration of drug biotransformation and elimination during infection and inflammation.
@en
P2093
P304
P356
10.1016/S0163-7258(01)00165-6
P577
2001-11-01T00:00:00Z